VFA
CTMX icon

Virtus Fund Advisers’s CytomX Therapeutics CTMX Stock Holding History

Virtus Fund Advisers’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$339K Buy
+16,059
New +$333K ﹤0.01% 421

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TG
TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

Virtus Fund Advisers's CTMX Position: Q4 2017 in Review

Virtus Fund Advisers opened a new position in CytomX Therapeutics (CTMX) in Q4 2017: 16,059 shares worth $339K. The stake represents ﹤0.01% of the portfolio and ranks #421 among its holdings.

119 funds tracked by Wall St. Rank hold CTMX as of Q4 2017.

  • Virtus Fund Advisers held 16,059 shares of CytomX Therapeutics worth $339K as of Q4 2017.
  • CytomX Therapeutics was a new Virtus Fund Advisers position in Q4 2017.
  • CytomX Therapeutics made up ﹤0.01% of Virtus Fund Advisers's portfolio in Q4 2017, its #421 holding.
  • 119 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q4 2017.

Based on Virtus Fund Advisers's 13F filing for Q4 2017, filed 9 Feb 2018.